A Study to Test the Effect of Cyclosporine on the Immune System of Patients With Early HIV Disease
Status:
Completed
Trial end date:
2000-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and effectiveness of low doses of
cyclosporine (CsA) in patients with early HIV infection and to evaluate its effect on the
immune system.
Activation of T cells (cells of the immune system) leads to HIV replication. Inhibition of
immune activation is therefore a potentially important area of therapy for patients with
early HIV infection. CsA is capable of decreasing T cell activation, which in turn may
decrease HIV replication.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)